Saudi Arabia NUPCO Medical Device Procurement: Framework Agreements, Localization Rules & Market Entry Guide (2026)

Why Understanding Saudi Arabia's NUPCO Medical Procurement Matters

Saudi Arabia is the largest healthcare market in the Gulf Cooperation Council (GCC), and the Saudi government is by far the dominant buyer of medical devices and supplies. The Kingdom's pharmaceutical and medical device market is valued at approximately SAR 30 billion for pharmaceuticals alone, with government purchasing representing 54% of total market spend. The Saudi medical device market specifically is estimated at $2-3 billion and growing, driven by massive infrastructure investment under Vision 2030.

At the center of this purchasing power stands NUPCO — the National Unified Procurement Company. Established by Royal Decree in 2009 and wholly owned by Saudi Arabia's Public Investment Fund (PIF), NUPCO is the largest centralized medical procurement, warehousing, and distribution entity in the Kingdom. Its annual procurement exceeds SAR 25 billion (~$6.7 billion), with the government tender market alone valued at SAR 21 billion (~$5.6 billion). NUPCO serves over 500 public hospitals and health centers and integrates with nearly 5,000 private pharmacies through its Wasfaty service.

For foreign medical device manufacturers, understanding NUPCO is no longer optional. In 2026, NUPCO has begun actively rejecting foreign bids when a local alternative exists — a policy backed by the Local Content and Government Procurement Authority (LCGPA) and the "Made in Saudi" program. Companies that fail to build local manufacturing partnerships or demonstrate local content will find themselves locked out of the Kingdom's largest procurement channel.

This guide provides a comprehensive overview of NUPCO's structure, the tender and procurement process, localization requirements, SFDA regulatory prerequisites, digital transformation initiatives, and practical strategies for market entry.

Saudi Arabia's Healthcare System and Vision 2030

Vision 2030 and Healthcare Transformation

Saudi Arabia's Vision 2030 program has fundamentally restructured the Kingdom's approach to healthcare. Under the National Health Transformation Program, the government is investing hundreds of billions of riyals to modernize healthcare infrastructure, expand access, and reduce dependence on imported medical products.

Key healthcare transformation targets include:

Initiative	Target	Current Status (2026)
Pharmaceutical localization	80% of production localized by 2030	40 factories covering ~36% of market demand
Local production growth	Sustained annual expansion	Growing at 5% annually
Medical exports	Increase non-oil exports	Exports exceeding SAR 1.5 billion
Infrastructure expansion	New hospitals and specialty centers	Multiple mega-projects underway
Digital health	Integrated national health platform	Sehhaty app and NPHIES operational

Government Dominance in Healthcare Purchasing

Saudi Arabia's healthcare sector is overwhelmingly government-driven. The Ministry of Health (MOH) operates the largest network of hospitals and primary care centers, while the Ministry of Defense, Ministry of Interior, and other government entities each maintain their own healthcare facilities. NUPCO serves as the centralized procurement arm across these government health agencies.

The scale of government healthcare purchasing creates a distinctive market dynamic: unlike markets where private sector sales dominate, success in Saudi Arabia's medical device market requires engagement with centralized government procurement processes. The government tender market alone — valued at SAR 21 billion — represents the single largest revenue opportunity for medical device companies in the Kingdom.

Key Government Health Entities

Entity	Role
Ministry of Health (MOH)	Operates the largest network of public hospitals and primary care centers
Ministry of Defense (MOD)	Operates military hospitals and healthcare facilities
Ministry of Interior (MOI)	Operates security forces hospitals and clinics
Saudi Health Council	Strategic health policy coordination
NUPCO	Centralized procurement, warehousing, and distribution for all government health agencies
SFDA	Regulatory authority for medical devices, pharmaceuticals, and food
LCGPA	Sets local content requirements and government procurement preferences

NUPCO: Organization and Role

Corporate Overview

NUPCO was established in 2009 by Royal Decree with authorized capital of SAR 1.5 billion. It is wholly owned by Saudi Arabia's Public Investment Fund (PIF) — the Kingdom's sovereign wealth fund and one of the largest sovereign investment vehicles globally, with assets exceeding $900 billion. NUPCO is headquartered in Riyadh and led by CEO Fahad Al-Shibl.

NUPCO's mission is to strategically improve healthcare facilities across all public hospitals and medical centers in the Kingdom through centralized procurement, supply chain management, and distribution services. It has signed formal agreements with the Ministries of Health, Defense, and Interior to serve as their unified procurement channel.

Scope of Operations

NUPCO's operations span the entire medical supply chain:

Function	Description
Centralized procurement	Tenders and framework agreements for pharmaceuticals, medical devices, equipment, and supplies
Warehousing	Logistics centers across the Kingdom, including 32,000 m² facilities in Madinah and Qassim
Distribution	Delivery to 500+ government hospitals and health centers
Unified Catalogue	Product catalogs for pharmaceuticals, medical equipment, supplies, and laboratory items
Wasfaty service	Connects hospitals and primary care with 4,942 private pharmacies across 172 cities
e-Marketplace	Digital procurement platform for medical supplies

Key Achievements (2024-2025)

NUPCO's operational scale and strategic importance have grown significantly in recent years:

• Secured SAR 2.5 billion ($667 million) in financing for healthcare suppliers
• Provided 7,919 medical items in a single year to 47 government health agencies
• National factories' share of procurement reached 17.6%
• Integrated with 4,942 pharmacies via the Wasfaty service across 172 cities
• Earned Procurement Excellence and Ethics Accreditation in 2025
• Opened logistics centers in Madinah and Qassim, each spanning 32,000 m²
• Launched digital healthcare marketplace for private clinics and SMEs (Q1 2025)

The NUPCO Tender and Procurement Process

Framework Agreements: The New Standard

NUPCO has shifted from fixed-volume tenders to Framework Agreements as the primary procurement mechanism for medical devices and equipment. This transition is significant for manufacturers because framework agreements establish pre-qualified supplier lists with agreed pricing, rather than committing to specific purchase volumes.

Framework agreements are organized by therapeutic area or equipment category (e.g., diagnostic imaging, orthopedic implants, cardiology devices). Once a supplier is awarded a framework agreement, government hospitals and health centers can place orders against the framework at the agreed terms without going through a new tender process for each purchase.

This shift benefits suppliers who secure framework positions — providing predictable access to the government market — but raises the stakes for tender participation. Missing a framework agreement can effectively lock a supplier out of the government market for the duration of the agreement term.

Tender Process Overview

The NUPCO tender process follows a structured sequence:

Step	Description
1. Tender publication	Tenders are published on the NUPCO website at nupco.com/en/tenders/
2. Tender booklet purchase	Suppliers purchase the tender booklet (e.g., SAR 28,750 for pharmaceutical framework tenders)
3. Submission	Suppliers prepare and submit bids by the specified deadline
4. Bid opening	Bids are opened and initial compliance checks performed
5. Technical evaluation	Technical committee evaluates bid compliance with specifications
6. Commercial evaluation	Price evaluation and comparison
7. Preliminary result	Initial award decision published
8. Award	Final contract or framework agreement awarded

Direct Purchase Channel

For smaller or urgent items, NUPCO uses a direct purchase mechanism rather than going through the full tender process. This channel is typically used for:

• Low-value items below tender thresholds
• Urgently needed supplies
• Items with limited supplier availability
• Supplementary orders against existing framework agreements

Supplier Registration

All suppliers must register with NUPCO before participating in tenders. The registration process requires:

Registration Requirement	Details
Company name	Legal entity name as registered in commercial register
Commercial Registration (CR) number	Valid Saudi CR or equivalent
SFDA certification	Valid SFDA establishment license and product authorizations
Contact details	Authorized representative contact information
Specialty	Therapeutic area or product category

For broader government procurement beyond NUPCO, suppliers should also register on the Etimad portal (the Saudi government procurement platform) and the Marsof platform for government tenders.

The Unified Catalogue System

NUPCO maintains four primary product catalogs that define which products are eligible for government procurement:

Catalog	Last Updated	Scope
Pharmaceuticals	March 2026	Prescription and OTC medications
Medical Equipment	February 2026	Capital medical equipment and devices
Medical Supplies	December 2025	Consumables, disposables, and surgical supplies
Laboratory Supplies	Periodic updates	Diagnostic reagents, lab equipment, and consumables

The Unified Catalogue serves as the definitive reference for what government hospitals can order through NUPCO. Products not listed in the catalogue are generally not available through government procurement channels, making catalogue inclusion a critical commercial objective for medical device manufacturers.

Catalogue listing requires:

• Valid SFDA MDMA (Medical Device Marketing Authorization)
• Compliance with applicable Saudi and international standards
• Acceptable pricing relative to reference benchmarks
• Compliance with local content requirements where applicable

Pricing and Pharmacoeconomic Requirements

SFDA Pharmacoeconomic Evaluation

The SFDA introduced the Pharmacoeconomic Evaluation Studies Guideline Version 1.1, effective July 1, 2025. While initially focused on pharmaceuticals, this framework increasingly applies to high-value medical devices, particularly those involving new technology or significant budget impact.

Key requirements under the guideline:

Parameter	Requirement
Cost-effectiveness threshold	SAR 50,000-75,000 per QALY (Quality-Adjusted Life Year)
Local data	Mandatory use of Saudi epidemiological and cost data
Analysis types	Budget Impact Analysis (BIA), Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA)
Applicability	New entities, biologics, and high-cost technologies
Real-World Evidence (RWE)	Encouraged as supporting evidence
Health Technology Assessment (HTA)	Integrated into evaluation framework

Pricing Considerations for Medical Devices

While pharmaceutical pricing follows formal pharmacoeconomic evaluation, medical device pricing in NUPCO tenders is determined through:

• Competitive bidding within framework agreements
• Reference pricing against previous procurement prices and international benchmarks
• Value-based assessment for innovative technologies
• Total cost of ownership analysis for capital equipment

Manufacturers should prepare comprehensive pricing dossiers that include cost-effectiveness data, budget impact analysis, and comparison with existing treatment alternatives when submitting NUPCO bids for higher-value devices.

Localization Requirements and Local Content Rules

The 2026 Enforcement Reality

The most significant development for foreign medical device manufacturers in 2026 is NUPCO's enforced localization policy. This is no longer aspirational — NUPCO is now actively rejecting foreign bids when a qualified local alternative exists. This policy is backed by the LCGPA and integrated into the "Made in Saudi" program.

Key Localization Requirements

Requirement	Details
"Made in Saudi" program	Requires 40% added local value for product approval
Local content calculations	Mandatory for all NUPCO tenders and framework agreements
Manufacturing depth	Companies must prove actual manufacturing capability, not just registration or distribution rights
SFDA-approved local manufacturing	Only SFDA-approved, locally manufactured products qualify for national tenders
LCGPA oversight	Local Content and Government Procurement Authority sets and enforces requirements

Small Contract Exemptions

For contracts valued at SAR 1 million (~$266,000) or less, local content preference requirements are waived. This provides a pathway for foreign suppliers to participate in smaller procurement opportunities while building toward larger framework agreements.

When Foreign Bids Can Still Win

Despite the localization push, NUPCO retains exceptions for foreign bids under specific conditions:

Exception Condition	Details
No local alternative	If no more than one technically compliant local bid is received, foreign bids remain eligible
Significant price advantage	If a foreign offer is at least 25% lower than the second-best qualifying local bid
Strategic technologies	Devices with no local manufacturing capability may receive preferential treatment
Urgent medical need	Emergency procurement can bypass standard localization preferences

Building Local Content

For foreign manufacturers, building sufficient local content to compete in NUPCO tenders requires a deliberate strategy:

• Technology transfer agreements with Saudi manufacturing partners
• Joint ventures with local medical device factories
• Local assembly or finishing operations that add measurable Saudi content
• Saudi workforce development — hiring and training Saudi nationals contributes to local content scores
• Local sourcing of raw materials and components where feasible

The Kingdom currently has 40 factories covering approximately 36% of pharmaceutical market demand, with local production growing at 5% annually. The government's target is to localize 80% of pharmaceutical production by 2030, and similar ambitions are being extended to medical devices.

Requirements for Foreign Medical Device Suppliers

SFDA Regulatory Prerequisites

Before participating in any NUPCO tender, foreign medical device manufacturers must complete SFDA registration. The SFDA regulates medical devices through the MDMA (Medical Device Marketing Authorization) pathway, with devices classified into four classes (A through D) based on risk.

Requirement	Details
MDMA registration	Required for all device classes; submitted via GHAD electronic system
Authorized Representative (AR)	Mandatory for all foreign manufacturers; AR holds the license on behalf of the manufacturer
SFDA establishment licensing	Required per MDS-REQ 9 V2.0
Technical file	Complete technical documentation required (MDMA 2 pathway since January 2022)
ISO 13485	Required for local suppliers and expected for foreign manufacturers

Establishment Types and Licensing

The SFDA recognizes several establishment types relevant to medical device procurement:

Establishment Type	Description
Local Manufacturers	Entities manufacturing devices within Saudi Arabia
Authorized Representatives	Saudi-based entities representing foreign manufacturers
Importers/Distributors	Entities importing and distributing medical devices
Warehouses	Facilities storing medical devices under controlled conditions
Service Providers	Entities providing installation, maintenance, or other device-related services

Complete Requirements Checklist for NUPCO Participation

Foreign suppliers seeking to participate in NUPCO procurement must satisfy requirements at three levels:

Regulatory Level (SFDA):

• MDMA registration for each product
• Authorized Representative appointment and licensing
• SFDA establishment licensing for the AR or local entity
• Compliance with Saudi labeling requirements

Procurement Level (NUPCO):

• NUPCO supplier registration
• Tender booklet purchase for each relevant framework
• Compliance with technical specifications
• Local content documentation and calculations

Government Platform Level:

• Registration on Etimad portal for government procurement
• Marsof platform registration
• Compliance with government procurement law

Regional Headquarters Requirement

Since January 2024, foreign companies pursuing Saudi government contracts (including NUPCO tenders) were initially required to establish a Regional Headquarters (RHQ) in Saudi Arabia, with the RHQ employing a minimum of 15 staff including at least 3 C-suite executives physically based in the Kingdom. However, the Saudi government has since introduced exemptions to this requirement — foreign companies without a Saudi RHQ can now bid on certain specialized government tenders, and the LCGPA has communicated a regulatory framework allowing exemptions for specific project types. The RHQ requirement still applies broadly, but manufacturers should monitor evolving LCGPA guidance for current applicability to their specific procurement opportunities. Manufacturers planning to compete for large NUPCO framework agreements should factor potential RHQ establishment into their market entry timeline and budget.

Managed Entry Agreements and Pricing Mechanisms

NUPCO and the Ministry of Health use several pricing mechanisms beyond standard competitive bidding:

Mechanism	Description
Price/Volume Agreements	Sliding-scale discounts based on delivered volumes — manufacturers commit to lower unit prices as procurement volumes increase
Outcome-Based Contracts	Payment-by-results arrangements where NUPCO links partial payment to demonstrated clinical outcomes or performance benchmarks
External Reference Pricing (ERP)	SFDA uses a basket of 34 reference countries to establish ceiling prices, per the SFDA Drug Pricing Rules 2023
Framework Pricing	Multi-year framework agreements with fixed or indexed pricing, typically covering 2-3 year periods

Manufacturers should prepare for NUPCO to request one or more of these mechanisms during framework agreement negotiations, particularly for high-cost or innovative devices.

The Wasfaty Service and Digital Transformation

Wasfaty: Connecting Public Healthcare with Private Pharmacies

NUPCO's Wasfaty service is a significant innovation in Saudi healthcare delivery. It connects government hospitals and primary healthcare centers with 4,942 private pharmacies across 172 cities, enabling patients to fill prescriptions at private pharmacies rather than waiting at hospital dispensaries.

Wasfaty Feature	Details
Pharmacy network	4,942 private pharmacies
Geographic coverage	172 cities across Saudi Arabia
Integration	Connected to NPHIES (National Platform for Health Insurance Exchange Services)
Patient access	Sehhaty app integration for prescription management
Impact	Reduced waiting times at hospital pharmacies; improved access

For medical device manufacturers, Wasfaty is relevant because it creates an additional distribution channel beyond traditional hospital supply. Devices and supplies dispensed through community pharmacies — such as glucose monitoring systems, wound care products, and respiratory devices — can reach patients through this network.

NUPCO's Digital Transformation

NUPCO has embarked on a comprehensive digital transformation program:

Initiative	Status	Impact
e-Marketplace	Operational	Online procurement platform for medical supplies
Digital healthcare marketplace	Launched Q1 2025	Serves private clinics and SMEs
AI-powered demand forecasting	Deploying	Predictive analytics for inventory management
Stock tracking	Operational	Real-time inventory visibility across logistics network
Predictive logistics	Developing	AI-driven supply chain optimization
Insurance e-claims integration	Operational	Connected to NPHIES for claims processing
Sehhaty integration	Operational	Real-time formulary and patient data access

The digital healthcare marketplace launched in Q1 2025 is particularly notable. It extends NUPCO's procurement capabilities beyond government hospitals to private clinics and small-to-medium enterprises (SMEs), creating a new commercial channel for medical device suppliers.

Strategic Recommendations for Market Entry

For Manufacturers with Existing SFDA Registration

Companies already registered with the SFDA should focus on:

1. Evaluate localization options immediately. NUPCO's rejection of foreign bids when local alternatives exist is not a future threat — it is current practice. Identify potential Saudi manufacturing partners and begin technology transfer discussions.

2. Pursue framework agreement inclusion. The shift to framework agreements means that missing a tender cycle can result in exclusion from the government market for the full agreement term. Monitor NUPCO's tender calendar and participate in every relevant framework.

3. Register on the e-Marketplace. The digital healthcare marketplace provides access to private clinics and SMEs, offering a commercial channel less dependent on localization requirements.

4. Prepare pharmacoeconomic dossiers. For higher-value devices, prepare cost-effectiveness analyses using Saudi epidemiological data and the SAR 50,000-75,000 per QALY threshold.

5. Engage with Wasfaty. If your products can be dispensed through community pharmacies, explore Wasfaty integration as a distribution channel.

For Manufacturers New to Saudi Arabia

Companies entering the Saudi market for the first time should:

1. Appoint a qualified Authorized Representative. The AR is your legal presence in the Kingdom. Choose an AR with experience in your therapeutic area and existing relationships with NUPCO.

2. Begin SFDA MDMA registration early. Product registration timelines range from 3-12 months depending on device class. Factor this into your market entry timeline.

3. Register on Etimad and NUPCO platforms simultaneously. Complete government procurement registrations in parallel with SFDA registration to avoid delays once product authorization is obtained.

4. Develop a localization roadmap. Even if you initially enter through smaller contracts (under SAR 1 million), plan for local manufacturing partnerships to compete in larger tenders.

5. Budget for local content investment. Building local content — whether through technology transfer, joint ventures, or local assembly — requires upfront investment. Include this in your market entry budget.

Partnership Strategies

Strategy	Advantage	Risk
Joint venture with Saudi manufacturer	High local content score; full tender eligibility	Significant capital commitment; partner dependency
Technology transfer agreement	Builds local manufacturing; satisfies LCGPA requirements	IP exposure; longer setup timeline
Local assembly operation	Moderate local content contribution; faster to implement	May not meet 40% threshold alone; limited content score
Distribution agreement with local partner	Fastest market entry; lower investment	Lower local content score; may limit tender competitiveness

Emerging Trends (2026)

1. Accelerating Localization Enforcement

The LCGPA is tightening enforcement of local content requirements across all government procurement. Medical device manufacturers should expect:

• Increasing minimum local content percentages
• More rigorous verification of local manufacturing claims
• Expanded product categories subject to localization mandates
• Greater scrutiny of "local content" calculation methodologies

2. Regional Procurement Network Expansion

NUPCO is exploring regional expansion into GCC and MENA procurement networks, potentially extending its centralized procurement model beyond Saudi Arabia. A Memorandum of Understanding with Grupo Elfa (Brazil) signed in October 2025 focuses on healthcare procurement, logistics, and digital efficiency — suggesting NUPCO's ambitions extend beyond the Kingdom's borders.

3. AI and Predictive Procurement

NUPCO's investment in AI-powered demand forecasting and predictive logistics is expected to reshape procurement patterns. Manufacturers who can integrate with NUPCO's digital systems and provide real-time inventory and supply data will have a competitive advantage.

4. Strategic Partnership Agreements

NUPCO has signed framework agreements with major global manufacturers that are reshaping market structure:

Partner	Agreement Area
Siemens Healthcare	Diagnostic imaging framework agreement
Philips Saudi Arabia	Diagnostic imaging framework agreement
BGI Genomics	Genetic testing contract
Sanofi	Local insulin production
Osteonic	Orthopedic implants
Grupo Elfa (Brazil)	Procurement, logistics, and digital efficiency MoU

These agreements signal NUPCO's preference for strategic, long-term partnerships with manufacturers who demonstrate commitment to the Saudi market — including local manufacturing investment.

5. Private Sector Market Growth

While NUPCO dominates government procurement, the Saudi private healthcare sector is growing rapidly under Vision 2030. The launch of NUPCO's digital marketplace for private clinics and SMEs reflects this trend. Manufacturers should develop dual-channel strategies covering both government (NUPCO) and private sector sales.

Practical Checklist

Regulatory Foundation

• Appoint a qualified Saudi Authorized Representative (AR)
• Classify devices under SFDA system (Class A-D)
• Submit MDMA applications via GHAD system
• Obtain SFDA establishment licensing
• Ensure ISO 13485 certification is current
• Complete Saudi-language labeling requirements

Procurement Readiness

• Register as a NUPCO supplier (company name, CR number, SFDA certification, contact details, specialty)
• Register on Etimad portal for government procurement
• Register on Marsof platform for broader government tenders
• Monitor NUPCO tender calendar at nupco.com/en/tenders/
• Purchase tender booklets for relevant framework agreements
• Prepare technical and commercial bid documentation

Localization and Local Content

• Calculate local content percentage for each product
• Identify potential Saudi manufacturing partners
• Evaluate technology transfer or joint venture opportunities
• Assess local assembly feasibility for "Made in Saudi" qualification (40% local value)
• Document local content calculations per LCGPA methodology
• Develop Saudi workforce hiring plan to support local content scores

Pharmacoeconomic and Pricing

• Prepare cost-effectiveness analysis using Saudi epidemiological data
• Develop budget impact analysis for the Saudi health system
• Benchmark pricing against existing NUPCO catalogue prices
• Prepare pharmacoeconomic dossier per SFDA Guideline Version 1.1
• Calculate pricing within SAR 50,000-75,000 per QALY threshold where applicable

Digital and Distribution

• Register on NUPCO e-Marketplace platform
• Evaluate Wasfaty integration for pharmacy-dispensed products
• Prepare digital integration capabilities for inventory and supply tracking
• Assess private sector distribution channels alongside NUPCO

Key Takeaways

1. NUPCO is the gateway to Saudi Arabia's government medical device market. With annual procurement exceeding SAR 25 billion and serving 500+ hospitals, NUPCO is the dominant procurement channel. Success in Saudi Arabia requires engagement with NUPCO's tender and framework agreement processes.

2. Localization is enforced, not aspirational. NUPCO is now rejecting foreign bids when local alternatives exist. The "Made in Saudi" program's 40% local content requirement and LCGPA enforcement mean that foreign manufacturers must build local manufacturing partnerships or face exclusion from major tenders.

3. Framework agreements have replaced fixed-volume tenders. The shift to framework agreements means that missing a tender cycle can result in exclusion from the government market for the full agreement term. Monitor NUPCO's tender calendar closely and participate in every relevant framework.

4. SFDA registration is the prerequisite, not the finish line. MDMA authorization via the GHAD system is required before any NUPCO participation. Budget 3-12 months for SFDA registration depending on device class, and plan your NUPCO tender timeline accordingly.

5. Digital transformation is creating new channels. NUPCO's e-Marketplace, Wasfaty service, and AI-powered procurement systems are changing how medical devices are bought and distributed in Saudi Arabia. Manufacturers who integrate with these digital platforms will have a competitive advantage in both government and private sector channels.

6. Pharmacoeconomic requirements are becoming more rigorous. The SFDA's Pharmacoeconomic Evaluation Studies Guideline (effective July 2025) establishes a SAR 50,000-75,000 per QALY cost-effectiveness threshold and mandates the use of Saudi epidemiological data. Prepare pharmacoeconomic dossiers early, particularly for high-value and innovative devices.